Zivo Bioscience Inc Cash Flow Conversion Efficiency
Zivo Bioscience Inc cash flow conversion efficiency. Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) has a cash flow conversion efficiency ratio of 0.062x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-210.70K) by net assets ($-3.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zivo Bioscience Inc (2003–2025)
Cash flow conversion efficiency of Zivo Bioscience Inc from 2003 to 2025. This chart illustrates how Zivo Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Zivo Bioscience Inc stock quote for real-time trading data and today's change.
Zivo Bioscience Inc Cash Flow Conversion Ratio Explained
Zivo Bioscience Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zivo Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zivo Bioscience Inc ranked by their cash flow conversion efficiency. Also see ZIVO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hindprakash Industries Limited
NSE:HPIL
|
0.004x |
|
Youngsin Metal Industrial Co. Ltd
KQ:007530
|
0.067x |
|
Torrent Capital Ltd
V:TORR
|
0.075x |
|
Europa Metals Ltd
JSE:EUZ
|
-0.110x |
|
TAS Offshore Bhd
KLSE:5149
|
0.143x |
|
Orege Société Anonyme
PA:OREGE
|
0.034x |
|
Emmbi Industries Limited
NSE:EMMBI
|
0.023x |
|
Otto Holding AS
IS:OTTO
|
0.053x |
Annual Cash Flow Conversion Efficiency for Zivo Bioscience Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Zivo Bioscience Inc from 2003 to 2025. Review ZIVO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.75 Million | $-3.29 Million | 0.877x | -89.53% |
| 2024-12-31 | $-514.90K | $-4.31 Million | 8.377x | +218.61% |
| 2023-12-31 | $-2.21 Million | $-5.80 Million | 2.629x | -99.61% |
| 2022-12-31 | $-10.62K | $-7.10 Million | 668.670x | +59486.24% |
| 2021-12-31 | $6.04 Million | $-6.80 Million | -1.126x | -592.01% |
| 2020-12-31 | $-11.31 Million | $-2.59 Million | 0.229x | -48.53% |
| 2019-12-31 | $-8.34 Million | $-3.71 Million | 0.445x | +97.87% |
| 2018-12-31 | $-22.28 Million | $-5.01 Million | 0.225x | -13.66% |
| 2017-12-31 | $-16.30 Million | $-4.24 Million | 0.260x | +39.36% |
| 2016-12-31 | $-13.62 Million | $-2.54 Million | 0.187x | -22.79% |
| 2015-12-31 | $-9.50 Million | $-2.30 Million | 0.242x | -43.70% |
| 2014-12-31 | $-6.37 Million | $-2.74 Million | 0.430x | +38.01% |
| 2013-12-31 | $-9.59 Million | $-2.99 Million | 0.311x | -30.56% |
| 2012-12-31 | $-3.96 Million | $-1.77 Million | 0.448x | -29.64% |
| 2011-12-31 | $-2.03 Million | $-1.29 Million | 0.637x | -57.89% |
| 2010-12-31 | $-951.68K | $-1.44 Million | 1.513x | +397.95% |
| 2009-12-31 | $-3.79 Million | $-1.15 Million | 0.304x | -83.13% |
| 2008-12-31 | $-519.60K | $-935.82K | 1.801x | -3.29% |
| 2007-12-31 | $-755.37K | $-1.41 Million | 1.862x | -25.79% |
| 2006-12-31 | $-832.54K | $-2.09 Million | 2.510x | -10.22% |
| 2005-12-31 | $-590.09K | $-1.65 Million | 2.795x | +140.67% |
| 2004-12-31 | $-1.10 Million | $-1.28 Million | 1.161x | +139.94% |
| 2003-12-31 | $-35.94K | $-17.39K | 0.484x | -- |
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more